FDA VCRP elimination poses "dilemma" for CIR panel in obtaining ingredient use data.

FDA VCRP ELIMINATION POSES "DILEMMA" FOR CIR PANEL as the voluntary safety review group considers how it will attain frequency of use data (the number of products in which an ingredient is used) for cosmetics ingredients, Cosmetic Ingredient Review Chairman Wilma Bergfeld, MD, Cleveland Clinic Foundation, stated. During CIR's May 19 meeting in Washington, D.C., Bergfeld proclaimed that cuts in FDA's cosmetics program including the suspension of the Voluntary Cosmetic Reporting Program, is a "little bit discouraging." She added that "hopefully" the situation "will be resolved" so CIR can obtain the "newest information" available.